Insertion and Removal of Sutureless Amniotic Membranes

Article Sidebar

pdf
Published: May 9, 2019
DOI: https://doi.org/10.22374/jded.v2i1.11
Keywords:
ocular surface disease, amniotic membrane, sutureless

Main Article Content

Nicholas Colatrella

Abstract

Treatments for ocular surface disease have evolved significantly over the past several years. Sutureless amniotic membranes are easy to insert in the office, and they give practitioners the ability to monitor healing without interfering with the penetration of ophthalmic medications. With their ability to reduce inflammation, prevent scarring, and enhance epithelial proliferation, AM should be considered as a viable treatment option for managing patients with ocular surface disease.


 

Downloads

Download data is not yet available.

Article Details

Issue
Vol. 2 No. 1 (2019): JDEOSD (Special Issue)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.

Author Biography

Nicholas Colatrella

Dr. Nicholas Colatrella is a residency trained optometrist, who is the medical director and owner of PineCone Vision Center.  Dr. Colatrella is board certified by the American Board of Optometry and the American Board of Certification in Medical Optometry.  Dr. Colatrella received his Bachelor of Science degree from Old Dominion University in Norfolk, VA, and his Doctor of Optometry with honors from the Illinois College of Optometry in Chicago.  He completed his residency in ocular disease at the Veterans Administration Medical Center in Cleveland, Ohio and served as the director of operations at Northeast Ohio Eye Surgeons.  
Dr. Colatrella is a fellow in the American Academy of Optometry, past Chair of its disease section and a founding chair of the Anterior Segment Section.  He was also the first of two Diplomates in Anterior Segment Disease of the American Academy of Optometry.  He is a member of the American Optometric Association, Past President of both the Minnesota Optometric Association and the Illinois College of Optometry Alumni Council.  He is an InfantSEE® Provider and has served as an examiner for the National Board of Examiners in Optometry.  He has been published several times and lectures nationally on various topics including LASIK, cataracts, pharmacology, dry eye and corneal diseases.  He is an adjunct professor for several Colleges of Optometry and routinely mentors optometry student externs.  Locally, he has served on the boards for the Sartell Area Chamber of Commerce and the City of Sartell’s Economic Development Commission.  Dr. Colatrella has proudly accepted numerous awards and was honored to accept the “Young Optometrist of the Year” award both in Ohio and Minnesota.  He was also acknowledged as one of Best and Brightest “Forty under 40” in the eye care industry by Vision Monday Magazine and humbly accepted the “Sartell Business of the Year” award.  Dr. Colatrella enjoys his children, biking, running, tri /duathlons, fantasy football and home improvement.

References

1. Dua HS, Gomes JA, King AJ, et al. The amniotic membrane in ophthalmology. Surv Ophthalmol 2004;49:51–77.
2. Rennie K, Gruslin A, Hengstschla¨ger M, et al. Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells Int 2012; 2012:721538.
3. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci 2001; 42:1539–1546.
4. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surf 2004; 2:177–187.
5. Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. Eye Contact Lens 2009; 35:172–175.
6. Ijiri S1, Kobayashi A, Sugiyama K, et al. Evaluation of visual acuity and color vision in normal human eyes with a sutureless temporary amniotic membrane patch. Am J Ophthalmol. 2007;144(6):938-942.